Subsequent studies by Liu et al. showed further support for the cleavage hypothesis in that the co-blockade of ADAM kinases during treatment of HER2+ BC in vivo and in vitro augmented the activity of trastuzumab [16]. Here, ERBB2 is linked to breast cancer.